Silence Therapeutics plc

Board/Management Information • Jul 30, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4964U

Silence Therapeutics PLC

30 July 2015

30 July 2015

Silence Therapeutics plc

("Silence" or "the Company")

Interim Board Change

Silence Therapeutics plc, AIM: SLN, a leader in the development and delivery of novel RNA therapeutics, announces that Ali Mortazavi, Chief Executive of Silence, has taken a temporary compassionate leave of absence for approximately two months from his role within the Company due to an acute illness in his family. The Company's Non-Executive Chairman, Dr. Alastair Riddell, will take on the role of Executive Chairman on an interim basis, until Ali Mortazavi's return.

Alastair Riddell joined the Board of Silence in November 2013 and was appointed Non-Executive Chairman in January 2015. He has 32 years' experience in the biopharmaceutical sector, including 15 years as CEO and Chairman of several UK biotechs. As CEO of Pharmagene, he completed a successful flotation on the UK main list and as CEO of Paradigm Therapeutics executed a trade sale to Takeda.

Enquiries:

Silence Therapeutics plc Alastair Riddell, Executive Chairman Timothy Freeborn, Finance Director & Company Secretary	Tel:  +44 (0)20 3700 9711
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel	Tel:  +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker) James Steel/ Oliver Jackson	Tel:  +44 (0)20 7418 8900
Media Enquiries FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert	Tel: +44 (0) 20 3727 1000

Notes to Editors

About Silence Therapeutics (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOARLMRTMBTTBFA